ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.

Background: Recurrent high-grade gliomas progressing after surgery and temozolomide plus radiation therapy have traditionally been treated using antiangiogenic drugs as the first-line therapy. Since the phase 3 EORTC 26101 trial showed no significant benefit of administering antiangiogenic drugs, th...

Descripción completa

Detalles Bibliográficos

Publicado en:	Acta Radiologica Vol. 61; no. 3; pp. 404 - 414
Autores principales:	Asenjo García, Beatriz, Navarro Guirado, Félix, Nagib Raya, Fátima, Vidal Denis, María, Bravo Rodríguez, Francisco, Galán Montenegro, Pedro
Formato:	Journal Article
Publicado:	Sage Publications Inc. Mar2020
Acceso en línea:	Ver este registro en EBSCOhost